Clinical Trial Results:
            A Phase II Study of BMS-354825 in Subjects with Myeloid Blast Phase Chronic Myeloid
Leukemia Resistant to or Intolerant of Imatinib Mesylate
Revised Protocol 01: Incorporates Amendment 03 and Administrative Letter dated 25-February-2005.
Amendment 01 country specific version 1.0 dated 2005-03-14
    
|     Summary | |
|     EudraCT number | 2004-002516-28 | 
|     Trial protocol | SE AT FI GB DK IT BE | 
|     Global completion date | 
                                    07 Jul 2007
                             | 
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | 
                                        No
                                 | 
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    08 Dec 2016
                             | 
|     First version publication date | 
                                    08 Dec 2016
                             | 
|     Other versions | |
|     Summary report(s) | CA180-006_Synopsis | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
